Canaccord analyst John Newman raised the firm’s price target on Atara Biotherapeutics (ATRA) to $21 from $13 and keeps a Buy rating on the shares. The firm said its target increase is based on its expectations for positive ATA3219 data in NHL and Lupus in early 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRA:
Questions or Comments about the article? Write to editor@tipranks.com